

Edgar Filing: CBOT HOLDINGS INC - Form 425

CBOT HOLDINGS INC  
Form 425  
June 14, 2007

Filed by Chicago Mercantile Exchange Holdings Inc. pursuant  
to Rule 425 under the Securities Act of 1933, as amended, and  
deemed filed pursuant to Rule 14a-6 under the Securities  
Exchange Act of 1934, as amended.

Subject Company: CBOT Holdings, Inc.

Subject Company's Commission File No.: 001-32650

On June 14, 2007, Chicago Mercantile Exchange Holdings Inc. issued the following communications regarding its proposed merger with CBOT Holdings, Inc.

6/14/2007

To the CME Community:

CME and CBOT are continuing to work closely together to complete our historic merger so we can begin delivering efficiencies and providing new value to you, our members, as well as our shareholders and our global customer base.

Earlier this week, we announced that we received clearance from the Department of Justice to complete our merger. Today, to address recent developments and reaffirm our commitment to completing our merger with CBOT, CME further enhanced our offer to all CBOT shareholders by revising the terms of our merger agreement. CME has authorized CBOT to pay a special one-time dividend to all CBOT shareholders, as well as offered eligible CBOT members holding exercise rights privileges (ERPs) an attractive and valuable way to address the perceived uncertainties around their ERPs. Additionally, CBOT has rejected ICE's revised proposal. Ultimately, we believe the enhanced offer will move us an important step closer to completing this valuable transaction by solidifying CBOT shareholder and member support for our merger.

Under the terms of the revised agreement:

All CBOT shareholders will receive a one-time dividend of \$9.14 per CBOT share, or a total of \$485 million. The dividend will be declared by CBOT before the close of the merger and paid immediately prior to the merger.

In addition, eligible holders of ERPs will be able to choose either:

A guarantee of at least \$250,000 in value per ERP following a final resolution of the ongoing ERP litigation in Delaware; or

The right to sell an ERP to the company for \$250,000 within 45 days after the completion of the merger.

CME has eliminated the cap of \$15 million on out-of-pocket costs (including attorneys' fees) incurred by the company with respect to its obligations to prosecute the ERP litigation and defend against any other proceedings brought to challenge the exercise rights.

A five-person committee of the Board of CME Group, including three CBOT directors, will have veto authority over rule changes, including member fees, that could materially impair CBOT member opportunity. This veto authority will extend to the 2012 Annual

Edgar Filing: CBOT HOLDINGS INC - Form 425

Meeting of Stockholders, an extension of three additional years from the original merger agreement.

In our agreement, eligible CBOT members wanting to seek realization of the value potential of their ERPs can choose a \$250,000 minimum value per ERP guarantee while preserving the right to receive potentially higher value at the final resolution or settlement of the litigation, which we estimate is up to \$1.5 million. Eligible ERP holders who prefer immediate liquidity can choose to sell their ERPs to us within 45 days following the completion of the merger.

We believe that there is no doubt that the CME/CBOT guarantee related to the perceived ERP uncertainty is superior to ICE's proposed ERP approach, and we will be meeting with CBOT shareholders over the next few weeks to discuss these enhancements and review the comprehensive value of our offer.

With the DOJ approval process successfully completed, this new value-enhancing ERP offer puts us in a strong position to bring this deal to closure. We look forward to your continued support and to next month's shareholder vote.

Sincerely,

### **Forward-Looking Statements**

This press release may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the benefits of the business combination transaction involving CME and CBOT, including future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on current beliefs, expectations, forecasts and assumptions of CME's and CBOT's management which are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited to, the satisfaction of conditions to closing, including receipt of shareholder, member, antitrust, regulatory and other approvals on the proposed terms; the proposed transaction may not be consummated on the proposed terms; uncertainty of the expected financial performance of the combined company following completion of the proposed transaction; the combined company may not be able to achieve the expected cost savings, synergies and other strategic benefits as a result of the proposed transaction; the integration of CBOT's operations with CME's may not be successful or may be materially delayed or may be more costly or difficult than expected; general industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations affecting domestic and foreign operations.

More information regarding other risks that may affect the parties' performance can be found in their filings with the Securities and Exchange Commission, including Item 1A of CME's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and their most recent quarterly reports on Form 10-Q. Copies of said reports are available online at <http://www.sec.gov> or on request from the CME. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Except for any obligation to disclose material information under the Federal securities laws, CME undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this press release.

### **Additional Information**

CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with the proposed transaction. The parties intend to file a supplement to the joint proxy statement/prospectus and mail such supplement to CME and CBOT shareholders as of the record date for the special meetings. This press release is not a substitute for the definitive joint proxy statement/prospectus, as supplemented, or any other documents CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus, as supplemented, and any other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction. The definitive joint proxy statement/prospectus is, and the supplement thereto and other documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC's Web site ([www.sec.gov](http://www.sec.gov)) or from Chicago Mercantile Exchange Holdings Inc., Shareholder Relations and Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding CME's directors and executive officers is available in CME's proxy statement for its 2007 annual meeting of shareholders, dated March 17, 2007. Additional information regarding the interests of such potential participants is available in the definitive joint proxy statement/prospectus, as supplemented, and the other relevant documents filed with the SEC.

Statements included in this press release relating to the ICE offer reflect the views of CME's management.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

CME EMPLOYEE LETTER

6/14/2007

Dear Team,

Today, CME and CBOT have revised their merger agreement to deliver greater value to all CBOT shareholders. Additionally, CBOT rejected the revised ICE proposal submitted earlier this week.

With the new terms, which are detailed in the attached press release, CME has enhanced the value of our offer to provide highly attractive choices to CBOT members regarding their CBOE exercise rights (ERPs), including an opportunity to continue to seek the upside potential for their ERPs that we believe can be achieved in the litigation currently underway in Delaware court.

The revised merger agreement provides a one-time dividend of \$9.14 per CBOT share, payable to all CBOT shareholders, to be declared by CBOT before the close of the merger and paid immediately prior to the merger. In addition, the agreement also provides eligible holders of an ERP the choice between:

A guaranteed minimum value of at least \$250,000 per ERP following a final resolution of the ongoing ERP litigation in Delaware; or

The right to sell an ERP to the company for \$250,000 within 45 days after the completion of the merger.

CME and CBOT have eliminated the cap of \$15 million on out-of-pocket costs (including attorneys' fees) incurred by the company with respect to its obligations to prosecute the ERP litigation and defend against any other proceedings brought to challenge the exercise rights.

The exercise right issue dates back to the creation of the CBOE by members of CBOT in 1973. At that time, CBOT full members were given the right, now called the ERP, to trade options at the neighboring CBOE without having to buy a membership. Since that time, CBOE has consistently worked to minimize or entirely eliminate the value of the ERP for CBOT shareholders. And, as CBOE is embarking on its own demutualization process and has announced its intentions to hold an initial public offering, it has an accelerated interest in resolving the exercise right issue. In December of last year, CBOE filed a motion in Delaware Chancery Court to terminate the exercise right upon the completion of CBOT's merger with CME. CME and CBOT do not agree with this position and are committed to obtaining a positive resolution for ERP holders. While ICE and CBOE proposed an undervalued solution to the ERP issue a few weeks ago, only CME and CBOT's offer preserves the upside potential for CBOT members wanting to seek realization of the value potential of their ERP after the litigation finally ends.

We believe that there is no doubt that the CME/CBOT guarantee regarding the ERP is superior to ICE's proposed approach, and we will be meeting with CBOT shareholders over the next few weeks to discuss these enhancements and review the comprehensive value of our offer.

With the DOJ approval process successfully completed, this new value-enhancing ERP offer puts us in a strong position to bring this deal to closure.

As we continue to move toward completion of our merger, we want to thank you once again for your hard work over the last seven months since we originally announced the CME/CBOT proposed merger. Your efforts are very much appreciated as we look forward to the shareholder vote on July 9.

Sincerely,

Craig Gill

**Forward-Looking Statements**

This press release may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that is intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the benefits of the business combination transaction involving CME and CBOT, including future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on current beliefs, expectations, forecasts and assumptions of CME's and CBOT's management which are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited to, the satisfaction of conditions to closing, including receipt of shareholder, member, antitrust, regulatory and other approvals on the proposed terms; the proposed transaction may not be consummated on the proposed terms; uncertainty of the expected financial performance of the combined company following completion of the proposed transaction; the combined company may not be able to achieve the expected cost savings, synergies and other strategic benefits as a result of the proposed transaction; the integration of CBOT's operations with CME's may not be successful or may be materially delayed or may be more costly or difficult than expected; general industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations affecting domestic and foreign operations.

More information regarding other risks that may affect the parties' performance can be found in their filings with the Securities and Exchange Commission, including Item 1A of CME's Annual Report on Form 10-K for the fiscal year ended December 31, 2006 and their most recent quarterly reports on Form 10-Q. Copies of said reports are available online at <http://www.sec.gov> or on request from the CME. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. Except for any obligation to disclose material information under the Federal securities laws, CME undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this press release.

**Additional Information**

CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with the proposed transaction. The parties intend to file a supplement to the joint proxy statement/prospectus and mail such supplement to CME and CBOT shareholders as of the record date for the special meetings. This press release is not a substitute for the definitive joint proxy statement/prospectus, as supplemented, or any other documents CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus, as supplemented, and any other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction. The definitive joint proxy statement/prospectus is, and the supplement thereto and other documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC's Web site ([www.sec.gov](http://www.sec.gov)) or from Chicago Mercantile Exchange Holdings Inc., Shareholder Relations and Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding CME's directors and executive officers is available in CME's proxy statement for its 2007 annual meeting of shareholders, dated March 17, 2007. Additional information regarding the interests of such potential participants is available in the definitive joint proxy statement/prospectus, as supplemented, and the other relevant documents filed with the SEC.

Statements included in this press release relating to the ICE offer reflect the views of CME's management.

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

Investor Presentation  
June 14, 2007

\*

\* Name effective upon transaction closing.

2

Discussion of Forward-Looking Statements

Forward-Looking Statements

This presentation may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT combined

company

after

the

completion

of

the

merger

that

are

intended

to

be

covered

by

the

safe

harbor

for

forward-looking

statements

provided

by

the

Private

Securities

Litigation

Reform

Act

of

1995.

These

statements

include,

but

are

not

limited

to,

the



benefits  
of  
the  
business  
combination  
transaction  
involving  
CME  
and  
CBOT,  
including  
future  
financial  
and  
operating  
results,  
the  
new  
company's  
plans,  
objectives,  
expectations  
and  
intentions  
and  
other  
statements  
that  
are  
not  
historical  
facts.  
Such  
statements  
are  
based  
on  
current  
beliefs,  
expectations,  
forecasts  
and  
assumptions  
of  
CME  
and  
CBOT's  
management  
which  
are

subject  
to  
risks  
and  
uncertainties  
which  
could  
cause  
actual  
outcomes  
and  
results  
to  
differ  
materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited  
of  
conditions  
to  
closing;  
including  
receipt  
of  
shareholder,  
member,  
and  
other  
approvals  
on  
the  
proposed  
terms;  
the  
proposed  
transaction  
may  
not  
be  
consummated  
on  
the  
proposed  
terms;  
uncertainty  
of  
the  
expected  
financial  
performance  
of  
CME

following  
completion  
of  
the  
proposed  
transaction;  
CME  
may  
not  
be  
able  
to  
achieve  
the  
expected  
cost  
savings,  
synergies  
and  
other  
strategic  
benefits  
as  
a  
result  
of  
the  
proposed  
transaction;  
the  
integration  
of  
CBOT  
with  
ME s  
operations  
may  
not  
be  
successful  
or  
may  
be  
materially  
delayed  
or  
may  
be  
more  
costly

or  
difficult  
than  
expected;  
general industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations in  
domestic  
and  
foreign  
operations.

For  
more  
information  
regarding  
other  
related  
risks,

see  
Item  
1A  
of  
CME's  
Annual  
Report  
on  
Form  
10-K  
for  
the  
fiscal  
year  
ended  
December  
31,  
2006.

Copies  
of  
said  
10-K  
is  
available  
online  
at  
<http://www.sec.gov>  
or  
on  
request  
from  
the  
CME.  
You

should  
not  
place  
undue  
reliance  
on  
forward-looking  
statements, which speak only as of the date of this presentation. Except for any obligation to disclose material information under  
securities  
laws,  
CME  
undertakes  
no  
obligation  
to  
release  
publicly  
any  
revisions  
to  
any  
forward-looking  
statements  
to  
reflect  
events  
or  
circumstances after the date of this presentation.

**Additional Information**

CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) regarding the proposed transaction. This material is not a substitute for the definitive joint proxy statement/prospectus or any other documents that CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus and other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction.

The  
definitive  
joint  
proxy  
statement/prospectus  
is,  
and  
other  
documents  
filed  
or  
to  
be  
filed  
by

CME  
and  
CBOT  
with  
the  
SEC  
are  
or  
will  
be,  
available  
free  
of  
charge  
at  
the  
SEC's  
Web  
site  
(www.sec.gov)

or  
from  
Chicago  
Mercantile  
Exchange  
Holdings  
Inc.,  
Shareholder  
Relations  
and  
Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.

-----& #45;-

CME  
and  
its  
directors,  
executive  
officers  
and  
other  
employees  
may  
be  
deemed  
to  
be  
participants  
in  
the  
solicitation

of  
proxies  
in  
connection  
with  
the  
proposed  
transaction.  
Information  
about  
CME's  
directors  
and  
executive  
officers  
is  
available  
in  
the  
definitive  
joint  
proxy  
statement/prospectus.

-----& #45;--

Statements  
included  
in  
this  
presentation  
relating  
to  
the  
ICE  
offer  
reflect  
the  
views  
of  
CME's  
management.

-----& #45;-

This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale is made.

would  
be  
unlawful  
prior  
to  
registration  
or  
qualification  
under  
the  
securities  
laws  
of  
any  
such

jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.



3  
Pro Forma Q107 ADV  
6,454  
741  
3,866  
3,866  
0  
2,000  
4,000  
6,000  
8,000

10,000

12,000

CBOT/CME

Eurex

CBOT/ICE

Euronext.liffe

NYMEX

Pro Forma ADV

Q107

contracts in 000s

10,320

4,607

Note:

[1] Eurex

and Euronext.liffe

include individual equity and equity index options

[2] NYMEX includes Clearport

[3] Sources are company press releases and analyst presentations

7,295

3,431

1,512

4

CME/CBOT Proposed Merger

Greater immediate and long term growth opportunities

OTC opportunities are larger with CME

Greater diversity of revenue

Complementary products increase revenue/growth synergies

CME and CBOT are operationally superior and can grow from Day 1

Both companies have proven track records of long-term growth

Greater synergy potential than ICE offer

Cost synergies highly certain and realizable  
(at least \$150M)

Revenue synergies are larger and we believe are  
more realizable (at least \$75M)

Best strategic alternative

Most long term value

5

CME/CBOT Proposed Merger

Minimal execution risk

Flawlessly integrated CCL in 9 months

Flawlessly integrated NYMEX in 2 months

Already have over seven months of detailed  
integration planning for CME/CBOT merger

Accelerated original trading floor and Globex  
consolidation dates

Globex  
Q1 2008  
Trading Floor  
Q2 2008

Unique benefits for members and customers  
Trading floor consolidation/expense reduction  
Decreases costs for members/member firms  
Increases sustainability of open outcry businesses  
Best strategic alternative  
Most long term value

6

Cash Dividend for **ALL**  
CBOT Shareholders

Provides immediate and substantial liquidity

\$9.14 dividend per CBOT share

Aggregate value of \$485M

Declared pre-close/Paid immediately prior  
to close

Full Member/ERP Holder:

27,338 shares = \$250K

7

CBOT/CME Enhanced Agreement Components -  
ERP

Provides full upside and minimum guarantee  
to full ERP members

Cap removed on exercise right legal defense expenses

OR

Option 1

Minimum

Guarantee +

Upside

Option 2

Early

Cash-Out

Eligible full member with ERP receives  
guarantee

of



minimum  
value  
of  
\$250K  
with  
potential to realize value substantially above  
through settlement or judgment  
Eligible full member with ERP may transfer  
ERP interest to CME in exchange for cash  
payment  
of **\$250K**  
(45 days post-closing)

8  
CBOE ERP Implied Equity Value  
\$1.5 million  
Implied equity value per membership  
[2]  
930  
1,331  
2,261

CBOE Full Members

CBOE ERP holders

Total CBOE potential memberships

\$3.3 billion

Implied equity value of CBOE

[1]

CBOE Implied Equity Value

\$3.3bn

CBOE Full

Members

41%

ERP

Holders

59%

\$1.9bn

\$1.4bn

[1]

Implied equity value based on Investment Banker market comp analysis; equity value could be higher if value of CBOE is higher

[2]

Assumes ERP CBOE members share equally

Maintains ability to achieve full value of ERP, retain trading right and benefit from upfront dividend payment

9

CME

CBOT

ICE

CBOT

Platform for Diversified Growth

CBOT/CME have much greater presence

across all major asset classes

CBOT/ICE

CBOT/CME

Note: CME ADV includes NYMEX products on CME Globex and ICE ADV includes ICE futures and NYBOT futures and options on futures

Q1 2007 Combined ADV by Product Line (*in 000 s*)

0  
2,000  
4,000  
6,000  
8,000  
Interest  
Rates  
Equities  
FX  
Comm  
Energy  
Metals  
6,671  
2,305  
555  
724  
586  
154  
3,032  
142  
15  
818  
531  
65  
Comm  
Energy  
Metals  
Interest  
Rates  
Equities  
FX  
8,000  
6,000  
4,000  
2,000  
0

10  
\$262,296  
\$38,111  
\$20,352  
\$6,783  
\$6,394  
\$0  
\$50,000  
\$100,000  
\$150,000  
\$200,000

\$250,000

\$300,000

Interest Rate

Market

FX Market

Credit Market

Equity Market

Commodity

Market

Larger, More Valuable OTC Growth Opportunities

ICE

Source:

June

2006

Notional

Value

Outstanding

per

March

2007

BIS

Quarterly

Review

CBOT/CME will have:

Largest global exchange-traded derivatives market

Largest global derivatives clearing house

Largest global exchange-traded derivatives customer  
base

Swapstream

IDBs active

in cash

treasuries

Corporate

bond

platforms

Repo

facilities

FX MarketSpace

CBOT/CME is better positioned to immediately pursue the  
full scope of OTC growth opportunities

11

Summary Timeline

Original merger agreement -

October 17, 2006

ICE offer rejected by CBOT -

May 11, 2007

Revised merger agreement -

May 11, 2007

DOJ clearance of merger agreement -

June 11, 2007

Revised ICE offer rejected -

June 14, 2007

CME/CBOT cash dividend

and ERP solution adopted -

June 14, 2007



CBOT member and  
CME/CBOT shareholder votes -  
July 9, 2007

12  
CBOT/CME Merger  
A Superior Combination

Best opportunity to create both short and long-term  
value for shareholders and members

Boards concluded that the CME proposal offered  
greater benefits overall for shareholders, customers  
and members

Clearly aligned with CBOT's strategic vision

Better positioned to pursue immediate and long-term growth opportunities

Entails low integration and execution risk

Better able to compete and win in changing global marketplace

**CME and CBOT Merger Prepared Remarks**

**June 14, 2007**

**John Peschier**

Thank you for joining us today to discuss the revised terms of the merger agreement between CME and CBOT. To obtain a copy of our release and accompanying slides for this call, please go to the CME web site under Investor Relations. This morning we will walk you through the revised terms, and the strategic considerations related to the merger announcement, and then we will open up the call for your questions. Before I turn this over to Terry Duffy, Executive Chairman of CME, I'll read the safe harbor language. Statements made on this call or included on the accompanying slides that are not historical facts are forward-looking statements. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or implied in any forward-looking statements. More detailed information about factors that may affect our performance and risks related to the merger may be found in our press release for the merger and in our filings by the CME and the CBOT with the SEC, which are available on our respective Web sites. Additional information about this transaction will be available on [cme.com](http://cme.com) and [cbot.com](http://cbot.com).

Now, I would like to turn the call over to Terry.

**Terry Duffy**

Thank you for joining us this morning. With me today are Craig Donohue, CME's Chief Executive Officer and Jamie Parisi, CME's Chief Financial Officer. We are also joined by our colleagues from the Chicago Board of Trade including Charlie Carey, CBOT Chairman, Bernie Dan, the President and CEO, and Glen Johnson, CBOT's Chief Financial Officer.

CME and CBOT are committed to completing our merger and delivering superior value to the shareholders and customers of both companies. As you can see from slides 3 through 5, our merger will create the largest and most diverse exchange in the world. Together, we will be well positioned to leverage significant new growth opportunities in the rapidly changing marketplace.

We believe we have larger and more achievable cost synergies than ICE, as well as stronger growth opportunities. We also believe our merger transaction is low risk in terms of integration and operational reliability—a key factor in a business that the world depends on for hundreds of trillions of dollars in risk transfer activities each year. Given the strength of our combination, it is not surprising that our competitors would oppose us—or that others would seek to intervene in our merger. But we remain steadfast in our resolve. We are extremely gratified that we have achieved another important milestone toward the completion of our merger: DOJ clearance. ICE's exaggerated claims last March of having intimate knowledge of the DOJ's position were both misleading and incorrect. Perhaps the credibility of their other claims will also not bear the test of time.

Today, we are pleased to announce a revised agreement that further addresses CBOT shareholders' interests while strengthening our ability to complete this important transaction. Our revised agreement provides significant additional value and cash liquidity to *all* CBOT shareholders. It also provides CBOT Full Members and ERP Holders a minimum guarantee as well as the potential to realize the full upside of their ownership interest in the Chicago Board Options Exchange. Additionally, our revised agreement further addresses CBOT members' interests in an effective fashion.

Before I turn it over to Craig to explain our revised terms, I would like to accentuate the fact that we believe the Exercise Right has significant value above the offer made by CBOE and ICE. We believe in the legal merits of the CBOT members' case, and we are putting our money where our mouth is.

We are confident CBOT shareholders and members will recognize the benefits of our proposed solution to the ERP issue. Unlike the ICE alternative, our proposal creates value for all CBOT shareholders. At the same time, it gives ERP Holders the ability to pursue the full worth of their rights if they so choose. With the DOJ approval process successfully completed, this new value-enhancing ERP offer puts us in a strong position to bring this deal to closure.

At this point, I would like to turn the call over to Craig, who will provide more details about the enhancements to our agreement.

**Craig Donohue**

Thank you, Terry. With this week's Department of Justice clearance, we are one important step closer to completing this historic transaction. We would like to thank the DOJ staff for their professionalism in reviewing our merger transaction and in closing their investigation. Throughout this process, we have remained confident, while explaining to you our thorough preparation for and understanding of the issues evaluated by the Department of Justice. Many of you who know us well know that we are professional and not grandstanders. Therefore, it is with great satisfaction today that we deliver on our commitment to achieving this important milestone.

We believe the enhancements to our offer will be the final ingredient to complete our merger, as we enhance value to all CBOT shareholders while providing a valuable guarantee to the exercise rights issue. Please turn to slide 6. Under the terms of the revised agreement, all CBOT shareholders will receive a one-time cash dividend of \$9.14 per CBOT share, or a total of \$485 million. For a Full Member/ERP Holder with 27,338 CBOT Class A shares, this equates to a cash dividend of \$250,000. The dividend will be declared before the close of the merger, and paid immediately prior to the close. Throughout this process, we have worked hard with the CBOT to ensure a transaction that is fair to all CBOT shareholders and we believe this cash dividend accomplishes that.

As Terry mentioned, we have heard that many CBOT Full Members view the CBOE/ICE proposal as defective and inadequate. Therefore, we have developed a guarantee and purchase offer that allows ERP Holders greater flexibility to cash out for immediate value or to remain in the litigation with a

substantial minimum guarantee. Turning to slide 7, unlike CBOE and ICE, we and the CBOT recognize that different CBOT shareholders have different preferences for realizing value from their Exercise Rights. Therefore, the first option provides a guarantee of receiving at least \$250,000 in value per ERP, while preserving the right to receive higher value if the litigation or a subsequent settlement with CBOE results in a greater recovery to the ERP Holder. Alternatively, eligible ERP Holders that do not wish to wait for the end of the litigation or any future settlement with CBOE can sell their ERP to CME for \$250,000 in cash within 45 days after the completion of the merger. In either case, the cash dividend described above and the minimum value guarantee of \$250,000 will ensure that Full ERP Holders who also hold 27,338 CBOT Class A shares receive at least \$500,000 in aggregate value. Importantly, we have also removed the \$15 million cap on the Exercise Right legal defense expenses.

If you turn to slide 8, you will see our assumptions of the potential value of the ERPs. Assuming an estimated IPO value of CBOE of \$3.3 billion, the potential ERP value would be \$1.5 million. This assumes the maximum number of ERPs of 1,331 are reassembled and that an ERP holder receives the same share as a CBOE member. As you know, a market in ERP interests already exists. We expect our minimum guarantee, Early Cash Out option, and strengthened position in the litigation, to further encourage market participants to reassemble the component parts necessary to realize the full value from any litigation or compromise settlement. We are providing \$250,000 of dividend value, another \$250,000 minimum value guarantee for the ERP.



As I mentioned earlier, the total cash dividend payment is \$485 million. The maximum ERP guarantee payment would be \$333 million. I would like to make two key points on this. First, we believe most ERP Holders will not exercise the Early Cash-Out Option and thus we expect to fall well short of the maximum. Secondly, CME Group, *and all of its shareholders*, would be the beneficiary of any value realized in the litigation or any settlement with CBOE above the minimum guarantee amount for the ERPs CME Group may acquire from those who opt to cash out early. We believe this structure provides significantly greater flexibility to ERP Holders than the CBOE/ICE proposal and substantially strengthens the position of the class plaintiffs in the ERP litigation. ERP Holders who remain in the litigation will now be joined by CME Group, which may be holding ERPs that are transferred to it in the Early Cash-Out Option described above, and CME Group will also have a significant economic interest in vigorously pursuing the litigation to maximize the recovery from the CBOE.

Our revised proposal also further addresses CBOT members' interests in an effective fashion. As you may recall, our merger agreement provides that 10 of 30 directors will come from CBOT and that, for a period of approximately 3 years, a 5 member committee that will include 3 CBOT directors will have veto rights on rule changes, including pricing policies, that materially impair business opportunities for CBOT members. Our revised proposal extends this period from 3 years to 5 years, or through the 2012 Annual Meeting of Shareholders. Additionally, as we have emphasized many times, CME and CBOT have maintained highly differentiated pricing strategies that provide member liquidity providers with very substantial discounts. For example, CME Eurodollars on

Globex and CME E-mini stock index futures fees are approximately 90 percent cheaper for member liquidity providers than for customers who are traditionally market takers. These policies have been in place for many years and we fully expect them to be continued given the importance of liquidity to the success of our business. We believe this structure provides significant assurances to CBOT members while preserving flexibility to the Board and management of the company in terms of future decision making.

I will turn the call over in a moment to Charlie and Bernie to offer their thoughts, but let me provide CME's overall perspective. First, the CME/CBOT merger is an absolute winner and positions us as the largest pure play derivatives exchange with relevant global products that span every major asset class, as you can see on slide 9. We are also uniquely positioned to participate in enormous OTC markets, as illustrated on the next slide, and our recent success with FXMarketSpace is a testament to that.

We are all convinced that our merger transaction has the potential to unlock tremendous value for our shareholders. We started this merger by announcing on October 17 our plans to create the world's premier derivatives exchange. We worked together to begin integration planning, and in March we were able to announce an acceleration of our planned migration of e-cbot products to CME Globex (now anticipated in the first quarter of 2008) and the consolidation of our trading floors to the historic CBOT building (now anticipated in the second quarter of 2008). In May, CBOT rejected the unsolicited offer from ICE, after a thorough and deliberate process, and CME and CBOT revised our merger agreement to include an increased exchange ratio, a fixed price tender

offer, and increased board representation. On Monday, the government weighed in after a thorough review of facts and data, and provided clearance of our deal with no conditions. Today, CBOT has again rejected the unsolicited ICE offer, and we have revised our merger agreement to benefit all CBOT shareholders. ICE has been rejected not once, but twice, as slide 11 illustrates.

Before I make my concluding remarks, I would like to address the fixed price tender offer that remains a part of our merger agreement. I would like to make one final comment with regard to the tender offer. We announced the fixed price tender to both return capital to all shareholders and to express our confidence in the strength of CME Group. If the stock trades through the \$560 level before the tender is complete, we will have accomplished one of our goals. Let me be clear that we are also committed to our other goal, the return of excess capital to our shareholders.

Economically, our equity transaction is more valuable to CBOT shareholders than the ICE proposal when one considers the strategic benefits of our transaction, the future growth potential and the significantly lower operational risks. Our exercise rights guarantee is significantly more flexible, and ultimately should be more valuable, to full members and ERP holders. Our business model and pricing strategy both of which are grounded in decades of history and actions that speak louder than words are more beneficial to CBOT shareholders who make their living trading and who have significant value in their trading rights and income potential as important customers of our exchanges. We firmly believe, taken as a whole, CME and CBOT shareholders to be far more compelling. Lastly, I want to thank CME and CBOT shareholders for their patience during this extended process. We look forward to the shareholder and member votes on July 9<sup>th</sup>.

With that let me turn the call over to Charlie.

**Charlie Carey**

Thank you Craig and thank you Terry. Good morning. I have just a few brief comments about the revised terms of the merger agreement and then Bernie will come on and say a few words as well.

First of all, with the DOJ announcement, the revised ICE proposal, and the revised CME Merger Agreement, this has been a week in which there was a lot of activity. We have carefully reviewed ICE and its proposal over the last few months, and we carefully reviewed and considered ICE's revised proposal. However, at the end of the day, we concluded that the revised CME Merger Agreement offers greater overall benefits to our shareholders and members. The dividend will provide enhanced value to all of our shareholders, while the put option and guarantee for the Exercise Right allows our members to make their own decision whether to sell now or stick with the Delaware litigation in hopes of a higher return. It is also a solution that can be done quickly and without approval of the court. Finally, the extension of the rule change committee to 2012 shows the CME's commitment to member rights and the business model that has made both of our exchanges so successful over the last few years.

A combination with the CME will transform the global derivatives markets and create efficiencies for customers and members while delivering significant benefits to all shareholders. It also presents significantly less integration and execution risk than a combination with ICE. Now, we look forward to the vote

on July 9th and to closing this transaction as soon as we can after that date. I would also like to thank all of our shareholders and members for their patience as we continue through this process. With that, I will hand the call over to Bernie Dan.

**Bernie Dan**

Thank you Charlie and again, thanks to Craig and Terry for walking you through the highlights of the revised CME merger agreement.

As I have said many times, our environment is changing rapidly, and all of us must anticipate those changes and be ready to adapt in order to compete on a global basis. This is precisely why a combination with CME better serves the interests of our shareholders, our customers, and the industry generally. The combination with ICE would take longer to integrate and would involve significantly greater execution risks than a combination with CME. It would also require us to focus on integration and platform migration while our competitors are focusing on product innovation and customer service, creating a significant risk to our competitive position in the industry.

CME's operating history, familiarity with CBOT's products and industry are significant factors in our decision. When you combine that with today's announcement with the increased dividend and flexible choice in exercise rights - we are confident we are offering an even greater and more compelling value for members and shareholders.

As always, I want to thank everyone for their support during this process.

I will now turn it back to Craig.

**Craig**

Thanks, Bernie. We would now like to open up the call to your questions.

***Forward-Looking Statements***

*This presentation may contain forward-looking information regarding Chicago Mercantile Exchange Holdings Inc. and CBOT Holdings, Inc. and the combined company after the completion of the merger that are intended to be covered by the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the benefits of the business combination transaction involving CME and CBOT, including future financial and operating results, the new company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based on current beliefs, expectations, forecasts and assumptions of CME and CBOT's management which are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Other risks and uncertainties relating to the proposed transaction include, but are not limited to the satisfaction of conditions to closing; including receipt of shareholder, member, and other approvals on the proposed terms; the proposed transaction may not be consummated on the proposed terms; uncertainty of the expected financial performance of CME following completion of the proposed transaction; CME may not be able to achieve the expected cost savings, synergies and other strategic benefits as a result of the proposed transaction; the integration of CBOT with CME's operations may not be successful or may be materially delayed or may be more costly or difficult than expected; general industry and market conditions; general domestic and international economic conditions; and governmental laws and regulations affecting domestic and foreign operations.*

*For more information regarding other related risks, see Item 1A of CME's Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of said 10-K is available online at <http://www.sec.gov> or on request from the CME. You should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. Except for any obligation to disclose material information under the Federal securities laws, CME undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date of this presentation.*

***Additional Information***

*CME and CBOT have filed a definitive joint proxy statement/prospectus with the Securities and Exchange Commission (SEC) in connection with the proposed transaction. This material is not a substitute for the definitive joint proxy statement/prospectus or any other documents CME and CBOT have filed or will file with the SEC. Investors and security holders are urged to read the definitive joint proxy statement/prospectus and any other relevant documents filed or to be filed by CME or CBOT because they contain or will contain important information about the proposed transaction. The definitive joint proxy statement/prospectus is, and other documents filed or to be filed by CME and CBOT with the SEC are or will be, available free of charge at the SEC's Web site ([www.sec.gov](http://www.sec.gov)) or from Chicago Mercantile Exchange Holdings Inc., Shareholder Relations and Membership Services, 20 South Wacker Drive, Chicago, Illinois 60606, Attention: Beth Hausoul.*

*CME and its directors, executive officers and other employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about CME's directors and executive officers is available in the definitive joint proxy statement/prospectus.*

*Statements included in this presentation relating to the ICE offer reflect the views of CME's management.*

*This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.*